Hepatic Expression of Apolipoprotein E Inhibits Progression of Atherosclerosis without Reducing Cholesterol Levels in LDL Receptor-Deficient Mice

Molecular Therapy

Volumn 1, Issue 2, 2000, Pages 189-194

  Tsukamoto, Kazuhisa ^a   Tangirala, Rajendra K ^a   Chun, Sam ^b   Usher, David ^c   Puré, Ellen ^b   Rader, Daniel J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b WISTAR INSTITUTE   (United States)

^c UNIVERSITY OF DELAWARE   (United States)

Author keywords

Apolipoprotein; Atherosclerosis; Gene therapy; Gene transfer

Indexed keywords

APOLIPOPROTEIN E; CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN RECEPTOR;

ADENOVIRUS; ANIMAL; AORTA; ARTERIOSCLEROSIS; ARTICLE; BIOSYNTHESIS; BLOOD; DIET; DISEASE COURSE; GEL CHROMATOGRAPHY; GENE TRANSFER; GENETICS; HUMAN; HYPERLIPOPROTEINEMIA TYPE 2; IMMUNOHISTOCHEMISTRY; LIVER; METABOLISM; MOUSE; PATHOLOGY; TIME;

ADENOVIRIDAE; ANIMALS; AORTA; APOLIPOPROTEINS E; ARTERIOSCLEROSIS; CHOLESTEROL; CHROMATOGRAPHY, GEL; DIET; DISEASE PROGRESSION; GENE TRANSFER TECHNIQUES; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; IMMUNOHISTOCHEMISTRY; LIPIDS; LIVER; MICE; RECEPTORS, LDL; TIME FACTORS;

EID: 0034136833     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1006/mthe.2000.0028     Document Type: Article

References (51)

1. Plump A. S., Smith J. D., Hayek T., Aalto-Setälä K., Walsh A., Verstuyft J. G., Rubin E. M., Breslow J. L. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell. 71:1992;343-353.
2. Zhang S., Reddick R., Piedrahita J., Maeda N. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science. 258:1992;468-471.
3. Nakashima Y., Plump A. S., Raines E. W., Breslow J. L., Ross R. ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. Arterioscler. Thromb. Vasc. Biol. 14:1994;133-140.
4. Zhang S., Reddick R., Burkey B., Maeda N. Diet-induced atherosclerosis in mice heterozygous and homozygous for apolipoprotein E gene disruption. J. Clin. Invest. 94:1994;937-945.
5. Linton M. F., Atkinson J. B., Fazio S. Prevention of atherosclerosis in apolipoprotein E-deficient mice by bone marrow transplantation. Science. 267:1995;1034-1037.
6. Boisvert W., Spangenberg J., Curtiss L. Treatment of severe hypercholesterolemia in apolipoprotein E-deficient mice by bone marrow transplantation. J. Clin. Invest. 96:1995;1118-1124.
7. Bellosta S., Mahley R. W., Sanan D. A., Murata J., Newland D. L., Taylor J. M., Pitas R. E. Macrophage-specific expression of human apolipoprotein E reduces atherosclerosis in hypercholesterolemic apolipoprotein E-null mice. J. Clin. Invest. 96:1995;2170-2179.
8. Fazio S., Babaev V., Murray A., Hasty A., Carter K., Gleaves L., Atkinson J., Linton M. Increased atherosclerosis in mice reconstituted with apolipoprotein E null macrophages. Proc. Natl. Acad. Sci. USA. 94:1997;4647-4652.
9. Linton M. F., Fazio S. Macrophages, lipoprotein metabolism, and atherosclerosis: Insights from murine bone marrow transplantation studies. Curr. Opin. Lipidol. 10:1999;97-105.
10. Mahley R. W. Apolipoprotein E: Cholesterol transport protein with expanding role in cell biology. Science. 240:1988;622-630.
11. Schaefer E. J., Gregg R. E., Ghiselli G., Forte T. M., Ordovas J. M., Zech L. A., Brewer H. B. Jr. Familial apolipoprotein E deficiency. J. Clin. Invest. 78:1986;1206-1219.
12. Tsukamoto K., Smith P., Glick J. M., Rader D. Liver-directed gene transfer and prolonged expression of three major human apoE isoforms in apoE-deficient mice. J. Clin. Invest. 100:1997;107-114.
13. Tsukamoto K., Tangirala R., Chun S. H., Pure' E., Rader D. J. Rapid regression of atherosclerosis induced by liver-directed gene transfer of apolipoprotein E in apoE deficient mice. Arterioscler. Thromb. Vasc. Biol. 19:1999;2162-2170.
14. Metlay J. P., Witmer-Pack M. D., Agger R., Crowley M. T., Lawless D., Steinman R. M. J. Exp. Med. 171:1990;1753-1771.
15. Paigen B., Morrow A., Holmes P. A., Mitchell D., William R. A. Quantitative assessment of atherosclerotic lesions in mice. Atherosclerosis. 68:1987;231-240.
16. Rubin E., Krauss R., Spangler E., Verstuyft J., Clift S. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI. Nature. 353:1991;265-267.
17. Plump A., Scott C., Breslow J. Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse. Proc. Natl. Acad. Sci. USA. 91:1994;9607-9611.
18. Paszty C., Maeda N., Verstuyft J., Rubin E. M. Apolipoprotein AI transgene corrects apolipoprotein E deficiency-induced atherosclerosis in mice. J. Clin. Invest. 94:1994;899-903.
19. Tsukamoto K., Hiester K. G., Smith P., Usher D. C., Glick J. M., Rader D. J. Comparison of human apoA-I expression in mouse models of atherosclerosis after gene transfer using a second generation adenovirus. J. Lipid Res. 38:1997;1869-1876.
20. Gerdes L. U., Gerdes C., Klausen I. C., Faergeman O. Generation of analytic plasma lipoprotein profiles using two prepacked Superose 6B columns. Clin. Chim. Acta. 205:1992;1-9.
21. Yamada N., Inoue I., Kawamura M., Harada K., Watanabe Y., Shimano H., Gotoda T., Shimada M., Kohzaki K., Tsukada T. Apolipoprotein E prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbits. J. Clin. Invest. 89:1992;706-711.
22. Linton M. F., Hasty A. H., Babaev V. R., Fazio S. Hepatic Apo E expression is required for remnant lipoprotein clearance in the absence of the low density lipoprotein receptor. J. Clin. Invest. 101:1998;1726-1736.
23. Woollett L. A., Osono Y., Herz J., Dietschy J. M. Apolipoprotein E competitively inhibits receptor-dependent low density lipoprotein uptake by the liver but has no effect on cholesterol absorption or synthesis in the mouse. Proc. Natl. Acad. Sci. USA. 92:1995;12500-12504.
24. Lever M. J., Jay M. T., Coleman P. J. Plasma protein entry and retention in the vascular wall: Possible factors in atherogenesis. Can. J. Physiol. Pharmacol. 74:1996;818-823.
25. Huang Y., von Eckardstein A., Wu S., Maeda N., Assmann G. A plasma lipoprotein containing only apolipoprotein E and with γ mobility on electrophoresis releases cholesterol from cells. Proc. Natl. Acad. Sci. USA. 91:1994;1834-1838.
26. Krimbou L., Tremblay M., Davignon J., Cohn J. Characterization of human plasma apolipoprotein E-containing lipoproteins in the high density lipoprotein size range: Focus on pre-β1-LpE, pre-β2-LpE, and α-LpE. J. Lipid Res. 38:1997;35-48.
27. Ji Z. S., Brecht W. J., Miranda R. D., Hussain M. M., Innerarity T. L., Mahley R. W. Role of heparan sulfate proteoglycans in the binding and uptake of apolipoprotein E-enriched remnant lipoproteins by cultured cells. J. Biol. Chem. 268:1993;10160-10167.
28. Zhong-Sheng J., Pitas R. E., Mahley R. W. Differential cellular accumulation/retention of apolipoprotein E mediated by cell surface heparan sulfate proteoglycans. J. Biol. Chem. 273:1998;13452-13460.
29. Huang D. Y., Weisgraber K. H., Strittmatter W. J., Matthew W. D. Interaction of apolipoprotein E with laminin increases neuronal adhesion and alters neurite morphology. Exp. Neurol. 136:1995;251-257.
30. Mazzone T. Apolipoprotein E secretion by macrophages: Its potential physiological functions. Curr. Opin. Lipidol. 7:1996;303-307.
31. Hara H., Yokoyama S. Interaction of free apolipoproteins with macrophages: Formation of high density lipoprotein-like lipoproteins and reduction of cellular cholesterol. J. Biol. Chem. 266:1991;3080-3086.
32. Zhang W.-Y., Paulette M., Kruth H. S. Apolipoprotein E produced by human monocyte-derived macrophages mediates cholesterol efflux that occurs in the absence of added cholesterol acceptors. J. Biol. Chem. 271:1996;28641-28646.
33. Smith J., Miyata M., Ginsberg M., Grigaux C., Shmookler E., Plump A. Cyclic AMP induces apolipoprotein E binding activity and promotes cholesterol efflux from a macrophage cell line to apolipoprotein acceptors. J. Biol. Chem. 271:1996;30647-30655.
34. Huang Y., von Eckardstein A., Wu S., Assmann G. Effects of the apolipoprotein E polymorphism on uptake and transfer of cell-derived cholesterol in plasma. J. Clin. Invest. 96:1995;2693-2701.
35. Huang Y., Zhu Y., Raabe M., Wu S., Weisenhutter B., Seedorf U., Maeda N., Assmann G., von Eckardstein A. Effects of genotype and diet on cholesterol efflux into plasma and lipoproteins of normal, apolipoprotein A-I-, and apolipoprotein E-deficient mice. Arterioscler. Thromb. Vasc. Biol. 17:1997;2010-2019.
36. Zhu Y., Bellosta S., Langer C., Bernini F., Pitas R. E., Mahley R. W., Assmann G., von Eckardstein A. Low-dose expression of a human apolipoprotein E transgene in macrophages restores cholesterol efflux capacity of apolipoprotein E-deficient mouse plasma. Proc. Natl. Acad. Sci. USA. 95:1998;7585-7580.
37. Miyata M., Smith J. D. Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and beta-amyloid peptides. Nat. Genet. 14:1996;55-61.
38. Ross R. Atherosclerosis - An inflammatory disease. New Engl. J. Med. 340:1999;115-126.
39. Kelly M. E., Clay M. A., Mistry M. J., Hsieh-Li H. M., Harmony J. A. Apolipoprotein E inhibition of proliferation of mitogen-activated T lymphocytes: Production of interleukin 2 with reduced biological activity. Cell. Immun. 159:1994;124-139.
40. Roselaar S. E., Daugherty A. Apolipoprotein E-deficient mice have impaired innate immune responses to Listeria monocytogenes in vivo. J. Lipid Res. 39:1998;1740-1743.
41. Riddell D. R., Graham A., Owen J. S. Apolipoprotein E inhibits platelet aggregation through the l-arginine: Nitric oxide pathway. Implications for vascular disease. J. Biol. Chem. 272:1997;89-95.
42. Browning P., Roberts D., Zabrentzky V., Bryant J., Kaplan M., Washington R., Panet A., Gallo R., Vogel T. Apolipoprotein E (apoE), a novel heparin-binding protein, inhibits the development of Kaposi's sarcoma-like lesions in BALB/c nu/nu mice. J. Exp. Med. 180:1994;1949-1954.
43. Nathan B. P., Bellosta S., Sanan D. A., Weisgraber K. H., Mahley R. W., Pitas R. E. Differential effects of apolipoproteins E3 and E4 on neuronal growth in vitro. Science. 264:1994;850-852.
44. Nathan B. P., Chang K. C., Bellosta S., Brisch E., Ge N., Mahley R. W., Pitas R. E. The inhibitory effect of apolipoprotein E4 on neurite outgrowth is associated with microtubule depolymerization. J. Biol. Chem. 270:1995;19791-19799.
45. Bellosta S., Nathan B., Orth M., Dong L., Mahley R., Pitas R. Stable expression and secretion of apolipoproteins E3 and E4 in mouse neuroblastoma cells produce differential effects on neurite outgrowth. J. Biol. Chem. 270:1995;27063-27071.
46. Libby P. Molecular bases of the acute coronary syndromes. Circulation. 91:1995;2844-2850.
47. Fuster V., Fallon J. T., Badimon J. J., Nemerson Y. The unstable atherosclerotic plaque: Clinical significance and therapeutic intervention. Thromb. Haemostasis. 78:1997;247-255.
48. Lee R. T., Libby P. The unstable atheroma. Arterioscler. Thromb. Vasc. Biol. 17:1997;1859-1867.
49. Manson J. E., Tosterson H., Ridker P. M., Satterfield S., Hebert P., O'Connor G. T., Buring J. E., Hennekens C. H. The primary prevention of myocardial infarction. New Engl. J. Med. 326:1992;1406-1416.
50. Smith J., Blair S. N., Criqui M. H., Fletcher G. F., Fuster V., Gersh B. J., Gotto A. M., Gould K. L., Greenland P., Grundy S. M. Preventing heart attack and death in patients with coronary disease. Circulation. 92:1995;2-4.
51. Gotto A. M. Cholesterol management in theory and practice. Circulation. 96:1997;4424-4430.